Go Pro
→ Pass by August 7… or wait until 2027? (From Crypto 101 Media) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$77.70
-3.7%		$70.51
$24.85
▼
$80.97
$6.89B0.231.14 million shs340,513 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$105.66
-3.7%		$90.33
$14.10
▼
$115.51
$7.00B-0.341.13 million shs371,991 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$50.88
-1.6%		$52.88
$26.76
▼
$59.30
$7.79B1.622.20 million shs1.61 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$30.77
-1.5%		$27.74
$13.50
▼
$44.60
$2.01B-1.03844,865 shs627,936 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+5.75%+4.79%+14.95%+24.91%+215.65%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-3.00%+2.13%+19.61%+86.90%+653.37%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+2.85%+4.42%-4.21%+31.73%+85.14%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-2.07%-0.13%+1.79%+57.51%+97.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$77.70
-3.7%		$70.51
$24.85
▼
$80.97
$6.89B0.231.14 million shs340,513 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$105.66
-3.7%		$90.33
$14.10
▼
$115.51
$7.00B-0.341.13 million shs371,991 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$50.88
-1.6%		$52.88
$26.76
▼
$59.30
$7.79B1.622.20 million shs1.61 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$30.77
-1.5%		$27.74
$13.50
▼
$44.60
$2.01B-1.03844,865 shs627,936 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+5.75%+4.79%+14.95%+24.91%+215.65%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-3.00%+2.13%+19.61%+86.90%+653.37%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+2.85%+4.42%-4.21%+31.73%+85.14%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-2.07%-0.13%+1.79%+57.51%+97.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.185.57% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$134.3025.93% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.44
Hold$63.0022.08% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$45.7150.72% Upside

Current Analyst Ratings Breakdown

Latest ZBIO, TGTX, ORKA, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$22.00 ➝ $32.00
8/14/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
8/14/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$45.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$200.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$165.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$151.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
8/7/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$65.00 ➝ $72.00
8/4/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$78.00
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,728.77N/AN/A$11.61 per share6.79
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$16.79 per shareN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$616.29M12.82$2.88 per share17.94$3.95 per share13.07
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M197.69N/AN/A$3.79 per share8.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%N/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$447.18M$2.7418.8319.472.1555.22%73.49%34.14%11/2/2026 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.99N/AN/AN/AN/A-122.45%-58.04%N/A

Latest ZBIO, TGTX, ORKA, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.12-$1.77-$0.65-$1.77$15.00 million$1.00 million
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/3/2026Q2 2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.3057$0.05-$0.2557$0.05$229.77 million$240.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.23
4.27
3.72
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.57
9.93
9.93

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
8.87%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A66.21 million50.66 millionN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290153.07 million139.49 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A65.18 million50.84 millionN/A

Recent News About These Companies

HC Wainwright Forecasts Higher Earnings for Zenas BioPharma
August 20 at 1:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971197
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18 at 4:15 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/18/3347237/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
HC Wainwright Predicts Higher Earnings for Zenas BioPharma
August 18 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-predicts-higher-earnings-for-zenas-biopharma-2026-08-18/
Zenas BioPharma's (ZBIO) "Buy" Rating Reiterated at Guggenheim
August 17 at 1:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965151
Zenas BioPharma's (ZBIO) "Outperform" Rating Reiterated at Wedbush
August 17 at 1:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965139
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-walleye-capital-llc-takes-531-million-position-in-zenas-biopharma-inc-zbio-2026-08-15/
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharmas-zbio-buy-rating-reaffirmed-at-guggenheim-2026-08-14/
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharmas-zbio-outperform-rating-reiterated-at-wedbush-2026-08-14/
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-issues-earnings-results-2026-08-13/
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-stock-price-down-66-on-disappointing-earnings-2026-08-13/
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344367/0/en/zenas-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Zenas BioPharma (ZBIO) Expected to Post Quarterly Earnings on Tuesday
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30950584
Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-zbio-projected-to-release-quarterly-earnings-on-tuesday-2026-08-04/
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-inc-nasdaqzbio-given-average-rating-of-moderate-buy-by-analysts-2026-07-29/
Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exome-asset-management-llc-takes-position-in-zenas-biopharma-inc-zbio-2026-07-28/
Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% Higher - Still a Buy?
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-trading-77-higher-still-a-buy-2026-07-27/
125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-125232-shares-in-zenas-biopharma-inc-zbio-bought-by-walleye-capital-llc-2026-07-24/
SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seb-asset-management-ab-invests-320-million-in-zenas-biopharma-inc-zbio-2026-07-24/
Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jennison-associates-llc-buys-shares-of-250000-zenas-biopharma-inc-zbio-2026-07-22/
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees
July 17, 2026  |  quiverquant.comQ
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329284/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$77.70 -2.98 (-3.69%)
As of 02:21 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$105.66 -4.03 (-3.67%)
As of 02:21 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$50.88 -0.81 (-1.57%)
As of 02:21 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$30.77 -0.48 (-1.54%)
As of 02:19 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas